A class action lawsuit has been filed against VistaGen Therapeutics Inc. on behalf of investors who purchased the company’s common stock between April 1, 2024, and December 16, 2025. The lawsuit alleges that VistaGen made false and misleading statements regarding the Phase 3 PALISADE-3 trial of its drug fasedienol for social anxiety disorder, concealing material adverse facts. Investors who suffered losses during this period may be eligible to participate in the litigation, with a lead plaintiff deadline set for March 16, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602161916NEWSFILECNPR____20260216_284065_1) on February 17, 2026, and is solely responsible for the information contained therein.